Answers are grounded in this paper and cite their sources.
This study compared the effects of megestrol acetate (MA) prophylactic (p-MA) versus reactive (r-MA) use for critical body-weight loss (>5% from baseline) during concurrent chemoradiotherapy (CCRT) in patients with advanced pharyngolaryngeal squamous cell carcinoma (PLSCC).
No takes yet. Share an insight, caveat, or question.
Lin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: